Publications
Publications
Show Results For
- All HBS Web
(1,027)
- Faculty Publications (265)
Drugs
→
Page 1 of 265
Results →
- August 2025
- Background Note
A Managerial Perspective on Clinical Trials
By: Arthur A. Daemmrich, Satish Tadikonda and William Marks
This note describes the history and regulation of clinical trials, managerial challenges related to pharmaceutical product testing, and current debates regarding prescription drug safety. Since clinical testing takes between five and seven years, and consumes up to 70... View Details
- July 2025
- Case
Insilico’s Rentosertib Dilemma: A Star in the Pipeline?
By: Michael Lingzhi Li, Brian Mao Fu and Billy Chan
In 2024, the AI biotech firm Insilico Medicine faced a pivotal decision about its new drug, Rentosertib. Discovered and designed using artificial intelligence to treat a lung disease, Rentosertib had successfully advanced to Phase II trials — a first in global... View Details
- July 2025
- Article
No Free Lunch? Welfare Analysis of Firms Selling Through Expert Intermediaries
By: Matt Grennan, Kyle R. Myers, Ashley Swanson and Aaron Chatterji
We study how firms target and influence expert intermediaries. In our context, pharmaceutical manufacturers provide payments to physicians during promotional interactions. We develop an identification strategy based on plausibly exogenous variation in payments driven... View Details
- June 2025
- Teaching Note
Market Dynamics and Moral Dilemmas: Novo Nordisk's Weight Loss Drugs
Teaching Note for HBS Case No. 324-114. View Details
- 2025
- Working Paper
Combining Complements: Theory and Evidence from Cancer Treatment Innovation
By: Rebekah Dix and Todd A. Lensman
Innovations often combine several components to achieve outcomes greater than the
“sum of the parts.” We argue that such combination innovations can introduce an understudied
inefficiency—a positive market expansion externality that benefits the owners of
the... View Details
- November 2024
- Supplement
AlphaGo (C): Birth of a New Intelligence
By: Shikhar Ghosh and Shweta Bagai
This case, the final of a three-part series, explores DeepMind's pivotal transition from mastering games to solving real-world scientific challenges. In December 2020, DeepMind's AI system AlphaFold 2 achieved a breakthrough by solving protein folding—a 50-year-old... View Details
Keywords: Autonomy; Deep Learning; Drug Discovery; Healthcare Innovation; Neural Networks; Scientific Research; Technology Startup; AI and Machine Learning; Technological Innovation; Research and Development; Business Model; Business Strategy; Open Source Distribution; Technology Industry; United States
- November 2024
- Teaching Note
Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams
By: Debora L. Spar and Julia M. Comeau
Teaching Note for HBS Case No. 323-039. In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At... View Details
Keywords: Pharmaceutical Companies; Technological And Scientific Innovation; Organ Donation; Health Care and Treatment; Health Disorders; Innovation and Invention; Growth and Development Strategy; Product Development; Pharmaceutical Industry; Medical Devices and Supplies Industry; United States; District of Columbia
- November 2024
- Article
The Health Costs of Cost Sharing
By: Amitabh Chandra, Evan Flack and Ziad Obermeyer
What happens when patients suddenly stop their medications? We study the health consequences of drug interruptions caused by large, abrupt, and arbitrary changes in price. Medicare’s prescription drug benefit as-if-randomly assigns 65-year-olds a drug budget as a... View Details
- October 2024 (Revised October 2024)
- Case
Parexel: Scaling Up and Industry Dynamics
By: Regina E. Herzlinger and Ben Creo
Through the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small, secondary cluster of firms into a major player with... View Details
- October 2024
- Case
Allurion: Competing in the Age of GLP-1
By: Satish Tadikonda, Rajiv Lal, David Lane and Sarah Sasso
Shantanu Gaur had built Allurion into a formidable business internationally, providing obesity patients with a less invasive option long before GLP-1 drugs became the latest craze. Selling Allurion's medical device across 60+ countries, he awaited FDA approval to bring... View Details
- October 2024
- Article
Medicare Part D Protected-Class Policy Is Associated with Lower Drug Rebates
By: Pragya Kakani, Michael Anne Kyle, Amitabh Chandra and Luca Maini
Medicare Part D does not allow plans to exclude drugs in six protected classes from their formularies, which may limit plans’ ability to negotiate rebates and lead to higher spending. We estimated the association between protected-class status, US-level estimated... View Details
- September 2024
- Case
Google Quantum AI
By: David B. Yoffie, Michael A. Cusumano and Matt Higgins
Quantum computing may be the most important nascent computing technology of the 21st century. It has the potential to impact industries ranging from drug discovery to cybersecurity. Google's Quantum AI is one of the leaders in quantum research. This case explores the... View Details
- September 2024
- Case
Myeloma Investment Fund
By: Kyle Myers and Scott Sawaya
This case explores a critical decision facing the Myeloma Investment Fund (MIF) as it evaluates two investment opportunities aimed at accelerating a cure for multiple myeloma.
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
- August 2024
- Article
How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?
By: Leemore S. Dafny, Kate Ho and Edward Kong
Drug copayment coupons to reduce patient cost-sharing have become nearly ubiquitous for high-priced brand-name prescription drugs. Medicare bans such coupons on the grounds that they are kickbacks that induce utilization, but they are commonly used by... View Details
- July 2024 (Revised July 2025)
- Case
Gates Ventures: Making Alzheimer's a Forgotten Past
By: Satish Tadikonda, William Marks, Shardule Shah and Calvin Marambo
After a personal journey and interest in Alzheimer's Disease (AD) by Bill Gates, Gates Ventures set out to find the best way to accelerate innovation in the field of AD. In partnership with the Alzheimer's Drug Discovery Foundation, Gates Ventures created the... View Details
- June 2024
- Article
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
By: Jason Shafrin, Jaehong Kim, Joshua T. Cohen, Louis P. Garrison, Dana A. Goldman, Jalpa A. Doshi, Joshua Krieger, Darius N. Lakdawalla, Peter J. Neumann, Charles E. Phelps, Melanie D. Whittington and Richard Willke
This study argues that value assessment conducted from a societal perspective should rely on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein. Recently developed value assessment inventories—such as the Second Panel on Cost-Effectiveness’s... View Details
- 2024
- Working Paper
Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency
By: Mosab Hammoudeh, Joshua Lev Krieger and Jiajie Xu
This paper investigates whether moving R&D from incumbents to startups can increase innovation. Using comprehensive drug development data, we examine the outcomes of drug projects licensed from large firms to startups. We find that these projects licensed to startups... View Details
- April 2024 (Revised July 2024)
- Case
Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs
By: Joseph L. Badaracco, Tom Quinn and John Schultz
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of... View Details
Keywords: Cost vs Benefits; Decisions; Judgments; Values and Beliefs; Global Strategy; Health Care and Treatment; Patents; Growth and Development Strategy; Growth Management; Product Positioning; Supply and Industry; Supply Chain; Corporate Social Responsibility and Impact; Mission and Purpose; Philanthropy and Charitable Giving; Opportunities; Social Issues; Equality and Inequality; Pharmaceutical Industry; Health Industry; Denmark; United States; Europe; China; India; Middle East; North Africa
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details